Influence of medical intervention on sympathetic activity in heart failure

de Milliano, P.A.R.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Increased myocardial
$[^{123}\text{I}]-\text{metaiodobenzylguanidine}$ uptake after enalapril treatment in patients with chronic heart failure


Heart 1996: 76:218-222
Summary

Introduction: Sympathetic nerve activity is increased in patients with chronic heart failure. Angiotensin converting enzyme inhibitors lower cardiac sympathetic activity in these patients, as can be deduced from increased myocardial cardiac β adrenoceptor density in an endomyocardial biopsy. However, the effect of angiotensin converting enzyme inhibitors on cardiac sympathetic neuronal function and activity has not previously been investigated, especially with regard to the use of a non-invasive technique. In this study we evaluated the effect of enalapril on cardiac sympathetic neuronal function using $^{[12]}$I-metaiodobenzyguanidine (MIBG), a noradrenaline analogon, and single photon emission computerized tomography (SPECT).

Methods: In 23 patients with chronic stable congestive heart failure and a left ventricular ejection fraction less than 0.40, cardiac MIBG SPECT was performed and plasma noradrenaline concentration was measured before and after 6 weeks treatment with enalapril. Quantification of cardiac MIBG uptake was performed by using the left ventricular cavity and a venous blood sample as a reference.

Results: Cardiac MIBG uptake increased significantly after enalapril treatment (p<0.02), indicating improved cardiac neuronal uptake function. Plasma noradrenaline concentration did not decrease significantly. Cardiac MIBG uptake was not related to plasma noradrenaline concentration.

Conclusion: Cardiac MIBG SPECT can be used to assess changes in cardiac sympathetic neuronal uptake function due to pharmacological intervention. Enalapril appears to improve cardiac sympathetic neuronal uptake function but does not affect plasma noradrenaline levels significantly in a group of patients with predominantly moderate heart failure. This probably supports the hypothesis that a restoration of cardiac neuronal uptake of noradrenaline is one of the beneficial effects of enalapril in these patients.
Introduction
In patients with congestive heart failure, angiotensin converting enzyme (ACE) inhibitors are known to reduce mortality and morbidity\(^1\) to improve haemodynamics\(^2\) and to inhibit the process of remodelling.\(^3\) The suppression of neurohormonal systems by ACE-inhibitors may contribute to some of these beneficial effects.\(^6\)

In congestive heart failure the sympathetic nervous system is activated, as is reflected by the increase in the concentration of plasma noradrenaline. In addition, in the failing myocardium an impairment of neuronal uptake of noradrenaline has been shown.\(^7\) Both the enhanced release of noradrenaline and the altered cardiac neuronal uptake may be responsible for the observed downregulation of \(\beta\)-adrenoceptors in patients with heart failure.\(^6\)

The neuronal uptake mechanism can non-invasively be assessed by \(^{123}\)I-metaiodobenzylguanidine (MIBG).\(^10\) MIBG shares similar uptake and storage mechanisms in the sympathetic nerve endings as noradrenaline.\(^11\) In contrast with noradrenaline, MIBG is not metabolised.\(^13\) Cardiac neuronal uptake of MIBG can be measured non-invasively by single photon emission computerized tomography (SPECT).

ACE-inhibitors are known to increase cardiac \(\beta\)-adrenoceptor density and to reduce cardiac sympathetic activity in patients with heart failure.\(^14\) It can be assumed that improvement of cardiac neuronal uptake, which has been demonstrated to be the predominant mechanism for terminating the action of noradrenaline on the \(\beta\)-adrenoceptors, may contribute to these findings.\(^15\)

The aim of this study was to measure non-invasively the effect of short term treatment with enalapril on cardiac neuronal uptake in patients with congestive heart failure, using a new method to quantify myocardial MIBG uptake.\(^16\)

Methods
Study design
We prospectively studied cardiac MIBG activity and hormonal variables in 26 patients who were treated with enalapril and served as their own controls. The protocol was approved by the Ethics Committee of the Academic Medical Centre. Written informed consent was obtained from each patient by one of the investigators.

Patient selection
Patients with stable chronic heart failure (New York Heart Association class II-IV) for at least two months, left ventricular ejection fraction < 0.40 and fixed medication for at least 2 weeks were included. We excluded patients who were treated with ACE-inhibitors or other drugs that can influence neuronal MIBG uptake (\(\beta\)-adrenoceptor agonists/antagonists and tricyclic antidepressants). All other medications were allowed provided that the dose was not changed.
Chapte rr  V

during the study. Patients with insulin dependent diabetes mellitus, hyperthyroidism, recent myocardial infarction (within the past 2 months), neurologic diseases, prior valve replacement and myectomy of the left ventricle were also excluded.

Treatment
Patients were initially treated with 2.5 mg enalapril twice a day. The dose was increased to 10 mg enalapril twice a day in two weeks and adjusted if symptomatic hypotension occurred. Enalapril was stopped when there was an allergic reaction or deterioration of renal function (30% increase in plasma creatinine concentration). After the titration phase of two weeks the highest tolerated dose was continued for four weeks. Efficacy variables were assessed before and after six weeks of treatment.

Cardiac [123I]-MIBG SPECT acquisition protocol
All patients received 100 mg potassium iodide orally to block thyroid uptake an hour before intravenous injection of 185 MBq [123I]-MIBG (specific activity > 0.2 TBq/mmol; Cygne B.V. Technical University Eindhoven, The Netherlands). To minimise non-neuronal uptake of MIBG, SPECT images were obtained after four hours bedrest (Siemens MultiSPECT3, medium-energy collimators). A 20% energy window centred on the 159 keV photopeak of $^{123}$I was used. Data collection was performed using 60 frames over 360 degrees, for 60 seconds per frame, 64*64 pixel matrix, zoomfactor of 1.23 and using the camera auto-contour facility. No attenuation correction was applied. Figure 1 shows an example of the effect of enalapril on myocardial MIBG uptake, in a patient with chronic heart failure.

Quantification of myocardial MIBG uptake
Myocardial MIBG uptake was measured by a previously described method. Briefly, cardiac short-axis slices were reconstructed. In each short-axis slice elliptic regions of interest were semi-automatically drawn over the left ventricular myocardium and left ventricular cavity. Volumes of interest were constructed and quantified using the Cardiac SPECT Analysis-tool package (CASPAN Version 1.1). At the time of SPECT acquisition, a venous blood sample was drawn and $^{123}$I activity was measured in duplicate using a gamma counter (Auto-gamma 5000, Packard Instruments Company, Downers Grove, Illinois, USA). Myocardial MIBG uptake was calculated from the ratio of average activity per voxel in the myocardium (M) and the ventricular cavity (C) times the $^{123}$I activity measured in a venous blood sample (BS) according to the equation:

All data were corrected for injected radioactivity and radioactive decay. All studies were blindly analysed.
Modification of neuronal function by enalapril

**Figure 1** Short-axis reconstruction of a cardiac $^{[12]}$I-metaiodobenzylguanidine SPECT acquisition in a patient with congestive heart failure. Cardiac uptake (A) before (20.9 Bq/ml/MBq dose) and (B) after 6 weeks therapy with enalapril (35.0 Bq/ml/MBq dose). C = left ventricular cavity, M = myocardium, L = liver. Yellow and white areas represent high and very high MIBG uptake respectively, whereas red areas represent low MIBG uptake.

**Hormone analysis**

Patients fasted from 0:00 a.m. on the day of investigation although medication was continued. Patients were not allowed to take products containing caffeine the day before study. At 8:00 a.m. an intravenous indwelling catheter was inserted in the median cubital vein. After the patient had rested in supine position for 30 minutes, blood pressure was measured non-invasively (Dinamap 845, Critikon inc. Tampa USA) and venous blood samples were drawn from the catheter. Blood samples were stored on ice for up to 10 minutes before they were processed. Plasma was stored at -30°C. Plasma noradrenaline concentration was determined by high performance liquid chromatography and electrochemical detection, after purification on Biorex 70 and concentration by solvent extraction. Atrial natriuretic peptide (ANP) was determined by radioimmunoassay (Nichols Institute Diagnostics, Wijchen, The Netherlands). Plasma Renin Activity (PRA) was determined by radioimmunoassay for angiotensin I.18

**Statistical analysis**

The Student t-test for paired data was used where appropriate, otherwise the Wilcoxon signed ranks test was used. Differences were regarded as being significant at a two-tailed probability of 0.05 or less. Correlations were expressed as the Pearson correlation coefficient.
Results

Twenty-six patients were enrolled into the study. Two patients did not complete the full study period; one died because of progressive heart failure and one stopped enalapril treatment because of exanthema. SPECT data of one patient could not be analysed owing to technical problems. Data from the remaining twenty-three patients were used for analysis. These patients remained clinically stable during the course of the study.

Fifteen patients (65%) were known to have coronary artery disease as shown by either coronary angiography or documented myocardial infarction. Eight patients (35%) were classified as having idiopathic cardiomyopathy. Baseline characteristics are shown in Table 1.

The average daily dose of enalapril was 13.5 ± 6 mg ranging from 5 to 20 mg. The mean PRA at baseline was 1.35 ± 0.71 ng/ml/h (normal value < 3.2 ng/ml/h).

Changes of variables from baseline to six weeks treatment are shown in Table 2. Plasma creatinine concentration did not change significantly. Systolic and diastolic blood pressure decreased significantly from 130 ± 12.8 to 119 ± 12.4 mmHg (p=0.001) and from 81 ± 9.6 to 73 ± 10.6 mmHg (p=0.001) respectively.

Myocardial MIBG uptake increased significantly from 16 ± 8 to 20 ± 10 Bq/ml/MBq injected dose; p<0.02 (Figure 2). Individual data points are shown in Figure 3.

The mean plasma noradrenaline decreased from 361 ± 177 to 300 ± 146 ng/l which was not significant. Plasma ANP decreased significantly from 283 ± 239 to 170 ± 141 ng/l; p<0.02 (Figure 2).

![Figure 2](image1.png)  
**Figure 2** Bar chart of percent changes of hormonal parameters after therapy with enalapril, *p<0.02. ANP = plasma atrial natriuretic peptide concentration, MIBG = cardiac [123I]-metaiodo-benzylguanidine uptake, NA = plasma noradrenaline concentration.

![Figure 3](image2.png)  
**Figure 3** Plot of changes in cardiac [123I]-metaiodobenzylguanidine uptake after therapy with enalapril. Individual data for each patient as well as the mean ± SD for the averaged results are shown.
Table 1 Baseline characteristics. Values are mean±SD.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Before mean(±sd)</th>
<th>After mean(±sd)</th>
<th>Difference 95%-CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIBG (Bq/ml/MBq)</td>
<td>16 (±8.45)</td>
<td>20 (±9.67)</td>
<td>-6.52 to -8.70</td>
<td>0.013</td>
</tr>
<tr>
<td>NA (ng/l)</td>
<td>361 (±177)</td>
<td>300 (±146)</td>
<td>-22.62 to 146.02</td>
<td>0.14</td>
</tr>
<tr>
<td>ANP (ng/l)</td>
<td>283 (±239)</td>
<td>170 (±141)</td>
<td>20.51 to 205.84</td>
<td>0.019</td>
</tr>
<tr>
<td>Creatinine (mmol/l)</td>
<td>75.6 (±17.3)</td>
<td>75.2 (±15.7)</td>
<td>-3.07 to 3.76</td>
<td>0.83</td>
</tr>
<tr>
<td>RRsyst (mmHg)</td>
<td>130 (±12.8)</td>
<td>119 (±12.4)</td>
<td>5.66 to 17.60</td>
<td>0.001</td>
</tr>
<tr>
<td>RRsyst (mmHg)</td>
<td>81 (±9.6)</td>
<td>73 (±10.6)</td>
<td>4.30 to 13.39</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Table 2 Changes after 6 weeks enalapril treatment. ANP = plasma atrial natriuretic peptide concentration, MIBG = cardiac [125I]-metaiodobenzylguanidine uptake, NA = plasma noradrenaline concentration, PRA = plasma renin activity, RRsyst = systolic blood pressure, RRdiast = diastolic blood pressure.

Discussion

In the failing human myocardium, increased concentrations of circulating noradrenaline, an increased neuronal release, and a reduced neuronal uptake of noradrenaline have been reported.7,8,19 These alterations result in an increased noradrenaline concentration in the synaptic cleft and are responsible for the myocardial β-adrenoceptor downregulation. To measure the effect of enalapril on the cardiac neuronal uptake of noradrenaline, we used a quantitative cardiac MIBG SPECT method.16

The present study is, as far as we know, the first to show an increase in myocardial MIBG uptake after pharmacological intervention in patients with heart failure. This suggests an improvement
of cardiac neuronal uptake function caused by enalapril treatment. This is accords with the in vitro experiments of Takatsu et al. who showed that cardiac MIBG uptake was increased in cardiomyopathic Syrian hamsters after treatment with cilazapril. Improved neuronal uptake results in a more adequate termination of the action of noradrenaline on the myocardial β-adrenoceptors. Therefore, our findings are consistent with those of Gilbert et al. who showed an increased myocardial β-adrenoceptor density in an endomyocardial biopsy and decreased coronary sinus noradrenaline concentration after twelve weeks lisinopril treatment of patients with heart failure.

The improvement of neuronal function by enalapril can be explained by two mechanisms. First, ACE-inhibitors may improve directly cardiac neuronal uptake of noradrenaline by reducing angiotensin II concentrations. It has been shown that angiotensin II prevents the neuronal uptake of noradrenaline. This local effect may result in an increased exposure of the myocytes to noradrenaline and a subsequent downregulation of the myocardial β-adrenoceptors in patients with heart failure.

Second, ACE-inhibitors are known to improve haemodynamics. This systemic effect may indirectly result in a reduced cardiac neuronal release and a restoration of neuronal uptake of noradrenaline. In the present study, haemodynamic improvement is supported by the decreased blood pressure and plasma ANP concentration, indicating a diminished afterload and preload respectively. However, this systemic effect of ACE-inhibitors seems to be of less importance because plasma noradrenaline concentration did not change significantly, reflecting unchanged systemic sympathetic activity.

The predominance of moderate heart failure in our group of patients probably accounts for the unchanged plasma noradrenaline concentration. It has been reported that ACE-inhibitors reduce plasma noradrenaline concentrations in patients with moderate heart failure to a lesser extent than in those with severe heart failure. The absence of a significant correlation between plasma noradrenaline concentrations and myocardial MIBG uptake is explained by the fact that plasma noradrenaline does not reflect cardiac sympathetic activity because cardiac noradrenaline spillover accounts for less than 3% of total body noradrenaline release. A possible limitation of the study is the small number of patients studied. Since each patient served as their own reference, a placebo treated control group was not studied. This was considered appropriate because no subjective end points were used. All variables were assessed automatically and were analysed blindly.

Myocardial MIBG uptake was measured within a short period of time without any change in the clinical situation and treatment of each patient. Therefore, it can be assumed that the condition under which MIBG uptake was measured remained the same during the course of the study. It might be anticipated that myocardial MIBG uptake in infarcted areas is lower than in viable
myocardium because of sympathetic denervation, and therefore the inclusion of patients with ischaemic cardiomyopathy may have influenced our results. With the present quantitation method it is not possible to assess segmental MIBG uptake. Therefore, MIBG uptake of the entire myocardium was determined. Furthermore, the inclusion of denervated myocardium in the measurement should have led to an underestimation of the effect of enalapril on myocardial MIBG uptake because reinnervation is unlikely to occur in this relatively short period of study. These data suggest that cardiac MIBG SPECT can be used as a non-invasive method to assess changes in cardiac sympathetic neuronal function caused by pharmacological intervention. Short term treatment with enalapril primarily improves cardiac sympathetic neuronal uptake function rather than reducing systemic sympathetic activity in subjects with predominantly moderate heart failure.

This finding suggests that in these patients the beneficial effects of enalapril are at least partly due to improvement of cardiac sympathetic neuronal uptake function as non-invasively measured by MIBG SPECT. Because decreased cardiac MIBG uptake has been associated with unfavourable prognosis, future studies must determine the relation between cardiac MIBG uptake and the beneficial effects of ACE-inhibitors on mortality and morbidity.

Acknowledgements
This research was supported by grants from the Netherlands Heart Foundation (grant 92-342) and Merck Sharp & Dohme.

References
63


